Skip to main content
. Author manuscript; available in PMC: 2017 Nov 21.
Published in final edited form as: N Engl J Med. 2013 Jun 2;369(2):122–133. doi: 10.1056/NEJMoa1302369

Figure 1. Clinical activity of concurrent and sequenced regimens of nivolumab and ipilimumab.

Figure 1

Representative spider plots show changes from baseline in the tumor burden, measured as the sum of products of perpendicular diameters of all target lesions, in patients who received the concurrent regimen of 1 mg/kg nivolumab + 3 mg/kg ipilimumab, the maximum tolerated dose, (panel A) and in patients who received the sequenced regimen of 1 mg/kg nivolumab after prior ipilimumab therapy (panel C). Red triangles indicate the first occurrence of a new lesion. Representative waterfall plots show maximum percentage response in baseline target lesions in all patients who received the concurrent regimen (panel B) or the sequenced regimen (panel D). For sequenced regimen cohorts (panel D), “*” denotes patients who had radiographic progression with prior ipilimumab treatment.